Major article efficacy and safety of ixekizumab vs

HIGHLIGHTS

• who: Revista da Sociedade Brasileira from the [1]Universidade Su00e3o Paulo, Faculdade Ribeiru00e3o Preto, Ribeiru00e3o Preto, SP, Brasil[6]. Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA. have published the research: Major Article Efficacy and safety of Ixekizumab vs, in the Journal: (JOURNAL)
• what: This study proposed that modulation of the inflammatory immune_response via one of the following targets: IL-6, IL-17, and IL-2 could improve clinical outcomes of COVID-19 patients when compared to the SOC treatment. The authors aimed to evaluate the efficacy and safety of ixekizumab . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.